1.Clinical Study of Interrelationship Between Cold Agglutinin Titers and Indirect Hemagglutination Titers in Children with Mycoplasma Pneumoniae Pneumonia During Recent 3 Years.
Jong Chan SHIN ; Jae Youn KIM ; Myung Ik LEE ; Soon Wha KIM ; Keun Chan SOHN ; Kyeung Eun JUNG
Journal of the Korean Pediatric Society 1989;32(7):915-925
No abstract available.
Child*
;
Hemagglutination*
;
Humans
;
Mycoplasma pneumoniae*
;
Mycoplasma*
;
Pneumonia*
;
Pneumonia, Mycoplasma*
2.Understanding the Current Status of Korean Heart Transplantation Based on Initial KOTRY Report.
Korean Circulation Journal 2017;47(6):858-860
No abstract available.
Heart Transplantation*
;
Heart*
3.Molecular Analysis of Oculocutaneous Albinism Patients in Korea.
Ji Hwan HWANG ; Sang Woong YOUN ; Jong Seong AHN ; Kyu Han KIM ; Kyoung Chan PARK
Annals of Dermatology 1997;9(3):182-187
BACKGROUND: Oculocutaneous albinism (OCA) is a genetic disorder of the melanin pigment system in which melanin synthesis is reduced or absent in the skin, hair, and eyes. OCA is classified into two major types, and tyrosinase-related OCA can be produced by mutations of the structural gene for tyrosinase enzyme (TYR gene). OBJECTIVE: The purpose of this study was to analyze the segregation of mutant alleles of the TYR gene in tyrosinase-negative and tyrosinase-positive Korean OCA patients and families. METHODS: We amplified exon I, II, and III of the TYR gene of Korean OCA patients and their families by polymerase chain reactions (PCR), and analyzed the mutations by restriction fragment length polymorphism (RFLP) analysis in exon I and single-strand conformation polymorphism (SSCP) analyses in exon II and exon III. RESULTS: Two tyrosinase-negative cases showed mutations in exon I. Four tyrosinase-nega-tive cases and one tyrosinase-positive case showed mutations in exon II, and one tyrosinase-neg- ative case showed mutations in exon III. In summary, we found three kinds of mutation in four tyrosinase-negative OCA patients and one tyrsinase-positive OCA patient. CONCLUSIONS: RFLP and SSCP analysis can provide a basis for a rapid and sensitive screening system to detect TYR gene mutations of Korean OCA patients and their families.
Albinism, Oculocutaneous*
;
Alleles
;
Exons
;
Hair
;
Humans
;
Korea*
;
Mass Screening
;
Melanins
;
Monophenol Monooxygenase
;
Polymerase Chain Reaction
;
Polymorphism, Restriction Fragment Length
;
Polymorphism, Single-Stranded Conformational
;
Skin
4.A Case of Congenital Lymphedema.
Chan Jon KIM ; Seung Hee CHOI ; Young Youn CHOI ; Soo JinNa CHOI ; Jong Soon KIM
Journal of the Korean Society of Neonatology 1998;5(1):90-94
Congenital lymphedema is a rare disorder of unknown etiology which affects the extremities, preponderantly the lower extremities, at or immediately after birth. We experienced a case of congenital lymphedema in a newborn with generalized edema on the left lower extremity. We performed lymphangioscintigraphy and MRI for diagnosis. Microlymphaticovenous anastomosis was done on 16 days after birth and the patient showed clinical improvement. We report this case with brief review of the related literature.
Diagnosis
;
Edema
;
Extremities
;
Humans
;
Infant, Newborn
;
Lower Extremity
;
Lymphedema*
;
Magnetic Resonance Imaging
;
Parturition
5.The Past, Present and Future of Heart Transplantation
In Cheol KIM ; Jong Chan YOUN ; Jon A KOBASHIGAWA
Korean Circulation Journal 2018;48(7):565-590
Heart transplantation (HTx) has become standard treatment for selected patients with end-stage heart failure. Improvements in immunosuppressant, donor procurement, surgical techniques, and post-HTx care have resulted in a substantial decrease in acute allograft rejection, which had previously significantly limited survival of HTx recipients. However, limitations to long-term allograft survival exist, including rejection, infection, coronary allograft vasculopathy, and malignancy. Careful balance of immunosuppressive therapy and vigilant surveillance for complications can further improve long-term outcomes of HTx recipients.
Allografts
;
Forecasting
;
Heart Failure
;
Heart Transplantation
;
Heart
;
Humans
;
Tissue Donors
6.The Past, Present and Future of Heart Transplantation
In Cheol KIM ; Jong Chan YOUN ; Jon A KOBASHIGAWA
Korean Circulation Journal 2018;48(7):565-590
Heart transplantation (HTx) has become standard treatment for selected patients with end-stage heart failure. Improvements in immunosuppressant, donor procurement, surgical techniques, and post-HTx care have resulted in a substantial decrease in acute allograft rejection, which had previously significantly limited survival of HTx recipients. However, limitations to long-term allograft survival exist, including rejection, infection, coronary allograft vasculopathy, and malignancy. Careful balance of immunosuppressive therapy and vigilant surveillance for complications can further improve long-term outcomes of HTx recipients.
7.A Case of Nail Dystrophy with Selective Immunoglobulin A Deficiency.
Youngkyoung LIM ; Jongeun LEE ; Hyun Jeong BYUN ; Chan Seong PARK ; Ji Hye PARK ; Jong Hee LEE ; Dong Youn LEE
Korean Journal of Dermatology 2019;57(1):41-43
No abstract available.
Immunoglobulin A*
;
Immunoglobulins*
8.Update on heart failure management and future directions.
Hong Mi CHOI ; Myung Soo PARK ; Jong Chan YOUN
The Korean Journal of Internal Medicine 2019;34(1):11-43
Heart failure (HF) is an important cardiovascular disease because of its increasing prevalence, significant morbidity, high mortality, and rapidly expanding health care cost. The number of HF patients is increasing worldwide, and Korea is no exception. There have been marked advances in definition, diagnostic modalities, and treatment of HF over the past four decades. There is continuing effort to improve risk stratification of HF using biomarkers, imaging and genetic testing. Newly developed medications and devices for HF have been widely adopted in clinical practice. Furthermore, definitive treatment for end-stage heart failure including left ventricular assist device and heart transplantation are rapidly evolving as well. This review summarizes the current state-of-the-art management for HF and the emerging diagnostic and therapeutic modalities to improve the outcome of HF patients.
Biomarkers
;
Cardiovascular Diseases
;
Diagnosis
;
Genetic Testing
;
Health Care Costs
;
Heart Failure*
;
Heart Transplantation
;
Heart*
;
Heart-Assist Devices
;
Humans
;
Korea
;
Mortality
;
Prevalence
;
Prognosis
9.Erratum: Update on heart failure management and future directions
Hong Mi CHOI ; Myung Soo PARK ; Jong Chan YOUN
The Korean Journal of Internal Medicine 2019;34(4):944-944
There is an additional information in the acknowledgments.
10.Cardiovascular Complications of Novel Anti-Cancer Immunotherapy: Old Problems from New Agents?
Woo-Baek CHUNG ; Jong-Chan YOUN ; Ho-Joong YOUN
Korean Circulation Journal 2020;50(9):743-753
Many novel anti-cancer therapies have dramatically improved outcomes of various cancer patients. However, it also poses a risk for cardiovascular complications as well. For the novel anti-cancer agent with which physicians does not have enough clinical experiences to determine the characteristics of cardiovascular complications, it is important to assess risk factors for cardiotoxicity before starting anti-cancer therapy. High-risk patient should be consulted to cardiologist before initiating anti-cancer therapy and pre-emptive cardiac function monitoring plan might be prepared in advance. The biomarkers, electrocardiography and echocardiography are useful tools for the detection of subclinical cardiotoxicity during anti-cancer therapy. This review article tried to suggest the cardiac function monitoring strategies for newly encountered potential cardiotoxic anti-cancer agents and to summarize the cardiovascular complications of novel anti-cancer immunotherapies including immune checkpoint inhibitor (ICI) and chimeric antigen receptor (CAR) T-cell therapy. ICIs can cause fatal myocarditis, which usually occurs early after initiation, and prompt treatment with high-dose corticosteroid is necessary. CAR T-cell therapy can cause cytokine release syndrome, which may result in circulatory collapse. Supportive treatment as well as tocilizumab, an anti-interleukin-6 receptor antibody are cornerstones of treatment.